Pharmaceutical

StemVacs-V by Res Nova Bio for Metastatic Breast Cancer: Likelihood of Approval

StemVacs-V is under clinical development by Res Nova Bio and currently in Phase II for Metastatic Breast Cancer.

Dec 27, 2024 - 06:00
StemVacs-V is under clinical development by Res Nova Bio and currently in Phase II for Metastatic Breast Cancer.
Read the original article

Tags:

Previous Article

Eisbach Bio positions HRD-targeting therapy to supplant PARP inhibitors

Next Article

Lidocaine by MEDRx for Postherpetic Neuralgia: Likelihood of Approval

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Dermavant maps out atopic dermatitis filing after positive Phase III data 

Dermavant maps out atopic dermatitis filing after posit...

Jan 13, 2024

Johnson & Johnson agrees to acquire Ambrx Biopharma for $2bn

Johnson & Johnson agrees to acquire Ambrx Biopharma for...

Jan 9, 2024

QBiotics wins FDA orphan status for rainforest-derived cancer drug

QBiotics wins FDA orphan status for rainforest-derived ...

Feb 16, 2024